Rapamycin

Rapamycin (sirolimus) is a macrocyclic lactone antibiotic discovered in 1972 in soil from Rapa Nui (Easter Island), FDA-approved in 1999 for preventing organ transplant rejection. It works by binding FKBP12 and inhibiting mTOR (mechanistic target of rapamycin), a central kinase that regulates cellular growth, protein synthesis, and autophagy. The longevity case rests on the NIA Interventions Testing Program finding from Harrison et al. 2009 (PMID 19587680) that rapamycin extended median and maximum lifespan in mice even when started in mid-to-late life — the first pharmacological agent to achieve this. Subsequent ITP publications replicated the finding across multiple dosing regimens and starting ages. Mannick et al. 2014 (PMID 25540326) showed improved influenza vaccine response in elderly humans on low-dose rapamycin, and Mannick 2018 (PMID 29720494) showed reduced respiratory infections. The PEARL trial (AgelessRx, published 2024) is the first purpose-designed human longevity RCT of rapamycin, showing good safety and modest body composition improvements. Rapamycin is considered 'most promising' because it has the strongest mechanistic-convergence evidence (mTOR pathway is conserved across species) combined with mouse lifespan data across the most diverse experimental conditions. However, its human longevity benefit remains unproven in the rigorous sense — the Mannick and PEARL data show safety and biomarker improvements, not lifespan or healthspan endpoints that would take decades to establish.

For longevity purposes, rapamycin is typically prescribed as 3-8 mg once weekly (pulsed dosing), with the common ranges being 3-5 mg for beginners, 5-6 mg for intermediate users, and 6-8 mg for advanced protocols. Some practitioners use biweekly 8-10 mg dosing or other intermittent schedules. This is substantially DIFFERENT from transplant dosing: transplant patients receive continuous daily rapamycin at 2-5 mg/day with target trough levels of 5-15 ng/mL maintained continuously. The key distinction is that continuous daily dosing progressively inhibits mTORC2 (in addition to mTORC1), which produces most of the metabolic side effects (hyperlipidemia, glucose intolerance, new-onset diabetes) seen in transplant patients. Weekly pulsed dosing selectively inhibits mTORC1 during the peak effect window while allowing mTORC2 recovery between doses, providing the longevity-relevant autophagy and senescence-modulation effects with a much milder metabolic side-effect profile. The weekly schedule aligns with rapamycin's long half-life (60-90 hours in most patients), producing a biologically meaningful mTORC1 inhibition window of roughly 24-96 hours after each weekly dose.

At weekly 5-8 mg longevity dosing, the most common side effect is stomatitis (oral ulcers resembling canker sores) occurring in approximately 10-30% of users, typically within 1-4 weeks of starting or increasing dose, and often improving with continued use. Other common side effects include mild gastrointestinal upset, modest lipid elevation (typically 10-20% LDL increase), mild fatigue in the first 1-2 weeks, occasional acne-like rash, and mild modest platelet count decreases. Less common but notable are modest glucose tolerance changes (usually mild at longevity doses), impaired wound healing (relevant for surgery or dental procedures), and rare pulmonary toxicity (rapamycin-induced pneumonitis, rare at longevity doses but serious when it occurs). The side-effect profile at longevity doses is substantially milder than at transplant doses where these effects can be pronounced. The most important safety measures are: laboratory monitoring every 3-6 months (CBC, lipids, HbA1c, liver function), complete avoidance of grapefruit and strong CYP3A4 inhibitors, holding rapamycin for 2-4 weeks before and after elective surgery, effective contraception for women of reproductive age, and prompt evaluation of any respiratory symptoms during use.

Yes, rapamycin can be prescribed off-label for longevity purposes in the United States, though the process requires finding a physician comfortable prescribing for this indication. Standard primary care practices and most specialist practices will not prescribe rapamycin off-label due to unfamiliarity or conservative practice patterns. The most accessible pathways are: (1) Longevity-focused telemedicine practices such as AgelessRx (the company behind the PEARL trial) who prescribe rapamycin as part of their longevity program following medical screening. (2) Concierge longevity physicians and practices (Private Medical, various independent practices) who prescribe rapamycin as part of comprehensive longevity care. (3) Some integrative or functional medicine practices that have incorporated rapamycin into their longevity offerings. (4) Peter Attia's practice and similar high-end longevity medicine practices for patients who are existing clients. After prescription, sirolimus (generic) is dispensed at standard retail pharmacies or specialty compounding pharmacies. Insurance typically does NOT cover off-label rapamycin, and cost is typically $50-150/month out-of-pocket for 5-8 mg weekly dosing. The process typically involves: initial consultation (usually telemedicine), baseline laboratory testing (CBC, CMP, lipid panel, HbA1c, liver function), review of medications and medical history for contraindications, informed consent regarding off-label use and unproven longevity benefit, prescription issuance, and ongoing follow-up with laboratory monitoring every 3-6 months.

Yes, rapamycin has important drug and food interactions that require attention. Food interactions: Grapefruit and grapefruit juice MUST be avoided completely — they dramatically increase rapamycin blood levels through CYP3A4 inhibition and can produce severe side effects. Seville oranges and pomelos have similar effects and should also be avoided. Other citrus fruits (regular oranges, lemons, limes) are fine. The drug can be taken with or without food. Drug interactions requiring specific attention: Avoid completely — St. John's Wort, ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir and other HIV protease inhibitors. Monitor closely — fluconazole, diltiazem, calcium channel blockers, certain SSRIs. Dose adjustment considerations — rifampin, carbamazepine, phenytoin (all reduce rapamycin levels through enzyme induction). Generally safe combinations — statins (often needed for managing rapamycin's modest lipid effects), ACE inhibitors (though angioedema risk may be slightly elevated), metformin (commonly combined for longevity protocols), NAD+ precursors (NMN, NR), most supplements in normal doses. Always discuss new prescriptions, supplements, or herbal remedies with your prescribing physician before adding them during rapamycin use.

Yes, but timing matters for optimizing both training adaptation and rapamycin longevity effects. Rapamycin inhibits mTORC1, which is a key pathway for exercise-induced muscle protein synthesis and hypertrophy. Taking rapamycin around resistance training sessions could blunt training adaptation to some degree. The practical strategy used by most athlete-users: dose rapamycin on a rest day or lowest-intensity day (commonly Sunday evening), do lighter training (Zone 2, skills, rest) in the 24-72 hours post-dose when mTORC1 inhibition peaks (days 1-3 post-dose), and do the hardest resistance training sessions 4-7 days post-dose when mTORC1 inhibition has declined substantially. Aerobic exercise (Zone 2, steady-state cardio) does not appear meaningfully affected by weekly pulsed rapamycin. Adequate protein intake (1.2-1.6 g/kg/day, higher for older adults) remains essential during rapamycin use to support muscle maintenance. For athletes in dedicated hypertrophy or competitive prep phases, some practitioners recommend holding rapamycin entirely or reducing dose frequency to biweekly. The trade-off is real: rapamycin's theoretical longevity benefits versus some degree of blunted muscle adaptation. Most recreational lifters find the weekly-with-timing approach works well and doesn't meaningfully compromise strength or hypertrophy gains. Elite athletes or those in peak competition prep may want to pause rapamycin during those specific periods.

Rapamycin and metformin are the two most-discussed longevity drugs, with overlapping but distinct mechanisms and evidence bases. Mechanism: Rapamycin directly inhibits mTOR complex 1 (mTORC1), the central growth-signaling kinase; metformin primarily activates AMP-activated protein kinase (AMPK) via mitochondrial complex I inhibition, which indirectly inhibits mTORC1. Both converge on caloric restriction mimicry but through different upstream entry points. Evidence strength: Rapamycin has stronger and more consistent mouse lifespan-extension data (NIA ITP replicated across conditions) and a clearer mechanistic story connecting the drug to aging pathways. Metformin has mixed mouse data (ITP negative or modest depending on schedule; other labs more positive) but strong observational human data (Bannister 2014 PMID 25041462 showing T2DM patients on metformin outlived non-diabetic controls). Dosing: Rapamycin is weekly 5-8 mg pulsed; metformin is daily 500-2000 mg continuous. Side effects: Rapamycin produces stomatitis, modest lipid elevation; metformin produces GI upset, potential B12 depletion. Exercise interaction: Metformin has documented exercise-adaptation blunting (Konopka 2019, PMID 31557590); rapamycin has less-documented similar concerns. Regulatory status: Both are prescription drugs; both are used off-label for longevity. Clinical positioning: Metformin is often chosen for prediabetic or diabetic patients; rapamycin for broader longevity optimization in metabolically healthy individuals. Combination use is debated — some protocols combine both; others use only one. The choice is typically driven by: baseline metabolic status (favoring metformin for dysmetabolic patients), fitness goals (metformin exercise-blunting is a bigger concern for athletes), and practitioner philosophy.

The PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) trial, conducted by AgelessRx, is the first purpose-designed placebo-controlled RCT of rapamycin for longevity indications in generally healthy adults. The trial enrolled 150 participants aged 50-85 in a randomized placebo-controlled design. Participants received either 5-10 mg weekly sirolimus or placebo for 48 weeks, with outcomes assessed on physical function, body composition, blood biomarkers, and safety. Initial results published in 2024 demonstrated: (1) Favorable safety profile with expected side effects (stomatitis most common) at acceptable rates and no serious adverse events clearly attributable to rapamycin. (2) Significant improvements in lean mass in women (increased lean muscle mass) with no change in men, possibly reflecting sex-specific mTOR biology. (3) Modest blood pressure improvements. (4) Self-reported quality of life improvements. (5) No significant changes in several other biomarkers that would be expected to improve if rapamycin were substantially extending healthspan. The trial was not powered to detect healthspan or lifespan endpoints — those would require much larger, longer trials. The key value of PEARL is establishing: safety and tolerability of low-dose weekly rapamycin in a non-transplant population over nearly a year; feasibility of conducting longevity RCTs in this population; and providing the first controlled trial data (versus observational prescribing) for the use case longevity-medicine practitioners have been doing for years. PEARL is part of a growing rapamycin longevity research ecosystem that also includes the Dog Aging Project (Matt Kaeberlein, University of Washington) and various academic trials.

The long-term safety of weekly pulsed low-dose rapamycin in non-transplant populations is not fully established, though accumulated evidence is reasonably reassuring. What we know: Transplant patients have taken much higher continuous daily rapamycin for 20+ years with well-characterized (though not desirable) side-effect profiles — this establishes that chronic exposure at high doses does not produce unexpected delayed toxicities in addition to the known side effects. The Mannick, Kraig, and PEARL trials demonstrate safety of low-dose pulsed rapamycin in non-transplant populations over months. Off-label longevity prescribing has accumulated probably 10,000+ patient-years of experience with no clear signal of unexpected long-term adverse events. What we don't know: Whether 20-30+ year exposure to low-dose weekly rapamycin produces effects different from shorter-term use. The specific risks include: sustained modest mTORC2 inhibition could produce progressive glucose tolerance decline in some individuals over years; impaired wound healing and infection clearance could become consequential during serious acute illness or injury in old age; the metabolic side effects (lipids, glucose) could require ongoing management with other medications; rare pulmonary toxicity remains possible; theoretical concern about infection response during acute serious illness. Concerns that appear overblown based on current evidence: cancer risk (no signal of elevated cancer incidence in long-term users; some evidence of reduced cancer incidence), immunosuppression (Mannick data suggest enhanced rather than impaired immune function at low doses), and accelerated aging (no evidence for this, despite the drug's cellular growth effects). The honest framing: rapamycin at longevity doses appears acceptably safe for a reasonable-risk longevity intervention, but 'acceptably safe' is a judgment that depends on individual risk tolerance, baseline health, and what you're hoping to achieve. The evidence does not yet support either casual dismissal of concerns or confident endorsement as clearly safe over decades.

Rapamycin's effects are largely biochemical and preventive rather than producing obvious subjective improvements in the short term. This makes assessing 'working' challenging, and most long-term users are making probabilistic bets based on mechanism rather than tracking specific objective improvements. That said, useful tracking approaches: Laboratory biomarkers — baseline and every 3-6 months, track lipids (HDL, LDL, triglycerides), fasting glucose and HbA1c, CBC with differential, hsCRP, liver function, and if available more advanced biomarkers like ApoB, Lp(a), and insulin. Expect: small LDL elevation (10-20%), stable or slightly decreased platelet count, minimal change in glucose at longevity doses. Biological age markers — if available and affordable, PhenoAge, GrimAge, or Horvath epigenetic clocks at baseline and annually. These are imperfect but are the closest we have to tracking biological aging trajectory. Body composition — DEXA or comparable at baseline and annually to track lean mass preservation (rapamycin may help in women per PEARL data). Physical function — grip strength, VO2max (if exercise-tested), 6-minute walk distance, or other functional measures at baseline and 6-12 months. Subjective markers — energy levels, recovery quality after exercise, sleep quality, cognitive function (self-assessment or formal testing), infection frequency. Most users will NOT notice obvious subjective improvements on rapamycin — the drug's value is largely preventive and biochemical rather than producing symptomatic benefit. Expect the benefits to be subtle and cumulative over years rather than dramatic and immediate. If side effects are disproportionate to perceived benefit after 6-12 months, reassess whether to continue. The honest framing: rapamycin is a bet on mechanism-based life extension that we cannot yet confirm is paying off; most users continue based on faith in the mechanism rather than personal verification of effect.